Clinical Trial

Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The overall objective of this study is to preliminarily evaluate the efficacy and safety of Survivin-targeted DC Cell Injection in the postoperative treatment of newly diagnosed glioblastoma.
Trial Details
NCT Number NCT07715097
Lead Sponsor Beijing Tricision Biotherapeutics Inc
Conditions Glioblastoma
Enrollment 30 participants
Start Date 2026-09-30
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20